Molecular Hydrogen for Rheumatoid Arthritis
Molecular hydrogen (H₂) is a therapeutic medical gas that has attracted scientific interest for its potential role in inflammatory diseases, including rheumatoid arthritis (RA). Since the landmark 2007 discovery that H₂ can selectively scavenge hydroxyl radicals, over 3,000 peer-reviewed studies have examined its effects on human health[^c8], with therapeutic effects reported across more than 160 disease models[^c1]. A 2023 systematic review of 23 randomized controlled trials in Frontiers in Nutrition found consistent reductions in oxidative stress markers across multiple conditions[^c9]. A 2026 systematic review of hydrogen therapy in musculoskeletal conditions identified 45 eligible studies (25 preclinical, 20 clinical trials) and concluded that H₂ shows promising adjunctive therapeutic potential via antioxidant, anti-inflammatory, and cytoprotective mechanisms[^c6][^c10]. In the context of RA, molecular hydrogen has been investigated for its antioxidant, anti-inflammatory, and immunomodulatory properties, targeting the oxidative stress-driven inflammatory feedback loops that characterize the disease[^c2].
Clinical evidence includes an open-label pilot study in which 20 RA patients who consumed hydrogen-rich water showed significant reductions in disease activity scores and oxidative stress markers[^c3], followed by a randomized, double-blind, placebo-controlled trial of intravenous hydrogen-saline infusions in 24 patients that confirmed significant DAS28 reductions and decreased levels of interleukin-6 and matrix metalloproteinase-3[^c4]. Additional studies have explored hydrogen's effects on immune cell populations, demonstrating modulation of multiple T cell and B cell subsets[^c5]. Newer delivery approaches, including oral solid hydrogen capsules for sustained release and nanomaterial-based systems for localized hydrogen generation at arthritic joints, have expanded the potential applications of hydrogen therapy for RA. Recent case reports have documented successful hydrogen therapy in complex RA-related conditions including Rhupus syndrome with multiple drug intolerances, with patients achieving clinical improvement and discontinuation of corticosteroids[^c14].
Despite encouraging findings, the evidence base remains preliminary. A 2026 systematic review concluded that while hydrogen may serve as a promising adjunctive therapy, the absence of large-scale standardized trials makes incorporation into routine clinical practice premature[^c6]. A 2026 perspective paper confirmed that no large-scale, multi-centre, randomised double-blind controlled trials exist for any hydrogen therapy indication[^c11]. The literature for most disease models consists of only a small number of studies with heterogeneous protocols[^c7]. No clinical study of hydrogen therapy for RA has included radiographic assessment of structural joint damage.
Emerging preclinical research has introduced novel nanomaterial-based approaches that combine hydrogen therapy with additional therapeutic modalities. A 2D calcium disilicide nanosheet platform demonstrated simultaneous anti-inflammatory and bone-regenerative effects in arthritic animal models, achieving better outcomes than anti-inflammatory treatment alone[^c12]. A pH/NIR-responsive hydrogen nanogenerator showed superior analgesic efficacy compared to conventional nonsteroidal anti-inflammatory drugs in pain models, addressing the clinical need for integrated pain and inflammation management in RA[^c13]. These developments, while still at the preclinical stage, suggest potential directions for future therapeutic strategies.